Publication | Closed Access
Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.
18
Citations
0
References
2015
Year
Endocrine OncologyBreast OncologyAdapt Her2+/hMedicinePharmacologyClinical TrialsGynecologyEndocrine TherapyBreast CancerNeoadjuvant Tdm1Cancer TreatmentOncologyRadiation OncologyDifferential EfficacyCancer ResearchEndocrine-related CancerHealth Sciences
506 Background: Evidence suggests differential efficacy of standard neoadjuvant chemo- + targeted therapy in HER2+ early breast cancer (eBC) according to hormone-receptor (HR) status. ADAPT HER2+/H...